{"meta":{"query_hash":"b440a9f20b63","filters":{"venue":"Generics and Biosimilars Initiative Journal"},"cohort_total":14,"direct_labels_cover":1,"predictions_cover":14,"exported":14,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b440a9f20b63","api":"https://metacan.xera.ac/api/v1/cohort?venue=Generics+and+Biosimilars+Initiative+Journal"},"results":[{"id":"W2320750953","doi":"10.5639/gabij.2014.0303.033","title":"Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Interchangeability; Extrapolation; Business; Medicine; Computer science; Mathematics; Internal medicine","score_opus":0.14093827632215705,"score_gpt":0.2574729309045367,"score_spread":0.11653465458237966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320750953","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044860043,0.04195291,0.21450157,0.25662524,0.002959707,0.0020720572,0.0050162226,0.0013120575,0.43070018],"genre_scores_gemma":[0.5483447,0.03154687,0.27378696,0.08242198,0.0011017813,0.00083694694,0.0024821837,0.0006723621,0.058806326],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9383691,0.013729008,0.004423173,0.0042632576,0.035696406,0.0035191136],"domain_scores_gemma":[0.8827066,0.03782088,0.008608777,0.0074495757,0.05983797,0.0035761206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05608427,0.0009801334,0.0011562356,0.00828206,0.00745676,0.016405733,0.005218816,0.005123756,0.0038285516],"category_scores_gemma":[0.1111573,0.0012435793,0.0022747165,0.006647883,0.01695126,0.0068900753,0.0064360555,0.014000309,0.0007193513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026883458,0.00010680822,0.013338724,0.0008728751,0.00010707358,0.000808605,0.010273238,0.0030018818,0.001514064,0.727787,0.041829184,0.20009166],"study_design_scores_gemma":[0.00012434453,0.00035410674,0.043200362,0.0058500883,0.00031846075,0.0012828052,0.007126111,0.007234767,0.0057195732,0.20054008,0.7277995,0.00044978142],"about_ca_topic_score_codex":0.9307001,"about_ca_topic_score_gemma":0.929262,"teacher_disagreement_score":0.9114079,"about_ca_system_score_codex":0.088592134,"about_ca_system_score_gemma":0.22011225,"threshold_uncertainty_score":0.64278394},"labels":[],"label_agreement":null},{"id":"W2326320320","doi":"10.5639/gabij.2015.0401.009","title":"Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges","year":2015,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Biosimilar; Perspective (graphical); Regulatory science; Business; Medicine; Computer science; Internal medicine; Pathology","score_opus":0.15669981788227194,"score_gpt":0.3526119372573578,"score_spread":0.19591211937508585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326320320","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037583522,0.013223012,0.00036131934,0.9683099,0.004682786,0.000023969815,0.00015196315,0.00003130573,0.012839892],"genre_scores_gemma":[0.022303792,0.032373697,0.0032729078,0.9164972,0.008452927,0.00004562907,0.00024780133,0.00006000431,0.016746096],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96518534,0.0062272693,0.0014486085,0.002297469,0.0178292,0.0070121884],"domain_scores_gemma":[0.9124854,0.01779922,0.002511688,0.0012395139,0.040491562,0.025472594],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.030162485,0.0016282225,0.0015730214,0.0031713136,0.008802048,0.016764553,0.0054748985,0.054588076,0.018170968],"category_scores_gemma":[0.040003087,0.000871756,0.0031602671,0.0038574224,0.013764778,0.0068128565,0.004658122,0.026792387,0.0023796842],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014292583,0.00010946408,0.0010559092,0.00048638615,0.00006111273,0.0008670548,0.00038074338,0.00088918593,0.00075869524,0.10825302,0.8481453,0.03885017],"study_design_scores_gemma":[0.00012414203,0.00012213712,0.0020403103,0.0008106948,0.000060520924,0.00044816785,0.00074089476,0.00064064603,0.00024633182,0.020074623,0.97456574,0.00012579479],"about_ca_topic_score_codex":0.87066215,"about_ca_topic_score_gemma":0.9070734,"teacher_disagreement_score":0.9698375,"about_ca_system_score_codex":0.08222409,"about_ca_system_score_gemma":0.4000431,"threshold_uncertainty_score":0.5965804},"labels":[],"label_agreement":null},{"id":"W2488281113","doi":"10.5639/gabij.2016.0502.016","title":"Biosimilars patent litigation in Canada and Japan: a comparative strategic overview and EU and US update","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen Canada","keywords":"Biosimilar; Business; International trade; Law and economics; Economics; Medicine; Internal medicine","score_opus":0.12163815628710273,"score_gpt":0.28716337448201146,"score_spread":0.16552521819490873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488281113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.092485055,0.7112317,0.0008063257,0.070805505,0.0012854537,0.00019523005,0.0063836947,0.00009997025,0.11670709],"genre_scores_gemma":[0.38588002,0.56426734,0.0018364222,0.030301286,0.0010490872,0.00007942432,0.0041130316,0.000092813665,0.012380504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889346,0.00077451207,0.00078884244,0.0006515524,0.0066627976,0.0021877724],"domain_scores_gemma":[0.9506458,0.0109374095,0.006650083,0.00038927785,0.027485706,0.0038917614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0085889,0.00060063193,0.00092203566,0.016279485,0.0047463486,0.009873789,0.0017450865,0.0041639875,0.005468463],"category_scores_gemma":[0.016404271,0.0005917024,0.0014206127,0.03491773,0.0042532277,0.0032287762,0.0020497807,0.0033571129,0.00048493597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015377346,0.00039732366,0.103399545,0.0076527116,0.0005569822,0.002746478,0.007217876,0.0012011261,0.0010225192,0.07559562,0.25166658,0.5470055],"study_design_scores_gemma":[0.00019606951,0.00038145384,0.37923926,0.009070789,0.001406406,0.002851523,0.017700665,0.00067657203,0.0012496678,0.0023223546,0.5846066,0.00029860472],"about_ca_topic_score_codex":0.9213666,"about_ca_topic_score_gemma":0.9679961,"teacher_disagreement_score":0.08773772,"about_ca_system_score_codex":0.08773772,"about_ca_system_score_gemma":0.14995211,"threshold_uncertainty_score":0.63658464},"labels":[],"label_agreement":null},{"id":"W2493092156","doi":"10.5639/gabij.2016.0502.014","title":"Adjusted indirect comparisons between generics – bioequivalence and interchangeability","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Bioequivalence; Medicine; Pharmacology; Computer science; Pharmacokinetics","score_opus":0.2569267108682741,"score_gpt":0.31465631857701165,"score_spread":0.05772960770873753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493092156","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.348903,0.04800359,0.4134516,0.006984215,0.0071936995,0.0070624766,0.07141212,0.00090606586,0.09608321],"genre_scores_gemma":[0.9158445,0.0020231835,0.0590383,0.0020156908,0.0009879383,0.0034680208,0.01060363,0.00030269896,0.0057160985],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.840991,0.12681325,0.009834121,0.007495538,0.013261871,0.0016042106],"domain_scores_gemma":[0.65871096,0.270904,0.023365568,0.033964198,0.011805334,0.001249809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07638894,0.0015881449,0.0026662848,0.0027389366,0.00074550876,0.0040226597,0.002192369,0.0016038379,0.029017001],"category_scores_gemma":[0.3064476,0.00052533066,0.0064453385,0.004711513,0.0020049708,0.005167329,0.003763452,0.0048111863,0.0020764957],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038155023,0.0010268808,0.16221039,0.018923232,0.11457642,0.0011102032,0.002769428,0.016018646,0.0031464892,0.19422203,0.040501464,0.4073398],"study_design_scores_gemma":[0.0071795327,0.011257097,0.34423518,0.0029705383,0.053128317,0.0030738548,0.0013517379,0.030468145,0.014340525,0.40165445,0.12932979,0.0010107841],"about_ca_topic_score_codex":0.0018776691,"about_ca_topic_score_gemma":0.00177485,"teacher_disagreement_score":0.07638894,"about_ca_system_score_codex":0.0018531987,"about_ca_system_score_gemma":0.0014877964,"threshold_uncertainty_score":0.40398818},"labels":[],"label_agreement":null},{"id":"W2547846819","doi":"10.5639/gabij.2016.0503.032","title":"Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Hematology; Medicine; Internal medicine; Intensive care medicine","score_opus":0.06043340861617394,"score_gpt":0.27414360920156383,"score_spread":0.2137102005853899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547846819","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021112638,0.018457161,0.000392619,0.972524,0.0025725942,0.0000067305646,0.0000867813,0.000012809499,0.0038361182],"genre_scores_gemma":[0.086086,0.09668904,0.0038071717,0.78663546,0.02452304,0.000060997903,0.00027719603,0.000055867997,0.001865284],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.977117,0.011803523,0.0023795941,0.0014704692,0.0049482184,0.0022811864],"domain_scores_gemma":[0.82461905,0.08502306,0.020561393,0.0022813636,0.039875235,0.027639937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037260257,0.00047354386,0.0010851775,0.001325158,0.0030311532,0.0114869755,0.0029888179,0.017401142,0.02249198],"category_scores_gemma":[0.1318112,0.00040860538,0.0017562029,0.002076293,0.007928106,0.011435318,0.0037071665,0.013421598,0.0025359879],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009821996,0.00047575447,0.020067036,0.0033685458,0.00027442383,0.0023357447,0.0033004542,0.0014770958,0.0012323125,0.07117858,0.5374986,0.3578093],"study_design_scores_gemma":[0.00033323668,0.001031219,0.028965162,0.017291186,0.00035835456,0.004999394,0.029157497,0.0012664249,0.00076759676,0.1324526,0.7828816,0.0004957003],"about_ca_topic_score_codex":0.015671032,"about_ca_topic_score_gemma":0.0303906,"teacher_disagreement_score":0.037260257,"about_ca_system_score_codex":0.007876244,"about_ca_system_score_gemma":0.02758125,"threshold_uncertainty_score":0.19705337},"labels":[],"label_agreement":null},{"id":"W3047360337","doi":"10.5639/gabij.2020.0901.005","title":"It is time to change US trade policy to foster access to medicines","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Biosimilar; Balance (ability); Business; Access to medicines; Sustainability; International trade; International economics; Economics; Economic growth; Political science; Medicine; Developing country; Law","score_opus":0.24197099643837727,"score_gpt":0.3549841684586827,"score_spread":0.11301317202030542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047360337","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038728872,0.002892733,0.0005946548,0.97838634,0.013505316,0.000009555081,0.00006751157,0.000121534846,0.0040350524],"genre_scores_gemma":[0.0087289605,0.0031600092,0.0034471627,0.97296405,0.0055726143,0.000038590413,0.0001209735,0.000093386625,0.0058743106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9786645,0.005639034,0.0014457515,0.0013373458,0.008201405,0.004711985],"domain_scores_gemma":[0.92158806,0.01846859,0.0063396827,0.0039563924,0.023303315,0.026343886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022548592,0.0010692766,0.001766738,0.0017110516,0.0053335587,0.018786974,0.0037561664,0.03305809,0.029786376],"category_scores_gemma":[0.08146176,0.00068285747,0.0022871916,0.0020369668,0.0077985395,0.015719527,0.0057043843,0.035610527,0.014901373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015787096,0.00033912095,0.00055673486,0.0002582429,0.000064255255,0.00022246543,0.00032166092,0.00041414922,0.0004597798,0.0602936,0.8907071,0.046205148],"study_design_scores_gemma":[0.00007510334,0.00009724546,0.0009172572,0.00064765546,0.00003100948,0.000108345565,0.001205278,0.00019449434,0.00023486173,0.058536347,0.9378926,0.000059808892],"about_ca_topic_score_codex":0.013085889,"about_ca_topic_score_gemma":0.019813629,"teacher_disagreement_score":0.03305809,"about_ca_system_score_codex":0.0073595806,"about_ca_system_score_gemma":0.036828917,"threshold_uncertainty_score":0.11924976},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3110075982","doi":"10.5639/gabij.2020.0903.022","title":"3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Workgroup; Medicine; Quality (philosophy); Health professionals; Political science; Medical education; Health care; Pharmacology; Adverse effect; Computer science; Law","score_opus":0.058383037059144174,"score_gpt":0.34017598766712337,"score_spread":0.2817929506079792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110075982","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022725366,0.036764685,0.011588325,0.45569268,0.12442553,0.0022784467,0.00785776,0.0014929499,0.33717427],"genre_scores_gemma":[0.2785938,0.025516734,0.021780754,0.114344336,0.025942743,0.0024466424,0.010133168,0.0014485574,0.51979333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933349,0.002461097,0.00037027962,0.00056629005,0.001847953,0.0014194504],"domain_scores_gemma":[0.99041885,0.0018547191,0.0006991134,0.00028159562,0.0040908284,0.0026549771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009504086,0.0013955601,0.00043164016,0.0012298111,0.0025413989,0.006160981,0.0014604324,0.004649667,0.05045625],"category_scores_gemma":[0.011388521,0.00044265017,0.00071319763,0.00056027086,0.0013803534,0.0022270032,0.0050832145,0.0058275186,0.011627721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019179772,0.00013082998,0.000784868,0.0007892854,0.000013185313,0.000637137,0.0029159673,0.0003694108,0.002244424,0.003546817,0.9428591,0.04551724],"study_design_scores_gemma":[0.0000103428765,0.000017445027,0.0011776069,0.00043914994,0.000004230055,0.00008772635,0.001161006,0.0000905047,0.00053224305,0.00047729435,0.995983,0.000019412879],"about_ca_topic_score_codex":0.020522757,"about_ca_topic_score_gemma":0.03685457,"teacher_disagreement_score":0.05045625,"about_ca_system_score_codex":0.010823895,"about_ca_system_score_gemma":0.01609252,"threshold_uncertainty_score":0.16879296},"labels":[],"label_agreement":null},{"id":"W3119789362","doi":"10.5639/gabij.2021.1002.008","title":"Variation in the prices of oncology medicines across Europe and the implications for the future","year":2021,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org","funders":"","keywords":"Reimbursement; Population; Medicine; Per capita; Gross domestic product; Erlotinib; Life expectancy; Health care; Economics; Cancer; Internal medicine; Economic growth; Environmental health","score_opus":0.05162742510960357,"score_gpt":0.30450677715381375,"score_spread":0.2528793520442102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119789362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9281012,0.040462684,0.0022934154,0.009511175,0.00025881364,0.000028738614,0.0056132125,0.000026043923,0.013704728],"genre_scores_gemma":[0.9908812,0.005768296,0.00085077825,0.0006368805,0.00009249177,0.000009788453,0.0013633629,0.000014129178,0.00038324675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841523,0.0004464803,0.00026026877,0.00038349815,0.0003807802,0.00011375604],"domain_scores_gemma":[0.9929299,0.0027713398,0.0028922753,0.00028014043,0.0008857401,0.00024066475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003126428,0.0001303439,0.00033978588,0.0012398219,0.00018181137,0.0017865305,0.00037943246,0.0004747253,0.0023351426],"category_scores_gemma":[0.011573506,0.00012744634,0.0007383445,0.0031619712,0.000489323,0.0014440536,0.0006015277,0.00052608957,0.00018940346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077451195,0.0000821744,0.80063975,0.0015521344,0.0014631796,0.0016208645,0.0016034889,0.005259543,0.0010980878,0.019220991,0.010441618,0.1562437],"study_design_scores_gemma":[0.000016865713,0.00007689804,0.972765,0.0004941884,0.00017044134,0.0010121485,0.0012246723,0.0010728001,0.00035831967,0.003353067,0.01941414,0.000041482588],"about_ca_topic_score_codex":0.0046742735,"about_ca_topic_score_gemma":0.0030511606,"teacher_disagreement_score":0.0046742735,"about_ca_system_score_codex":0.001167915,"about_ca_system_score_gemma":0.0007446762,"threshold_uncertainty_score":0.016534328},"labels":[],"label_agreement":null},{"id":"W3216742648","doi":"10.5639/gabij.2021.1003.016","title":"A critical review of substitution policy for biosimilars in Canada","year":2021,"lang":"en","type":"review","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Competition (biology); Business; Market competition; Public economics; Marketing; Medicine; Economics; Market economy","score_opus":0.21793994318783752,"score_gpt":0.38310764969058575,"score_spread":0.16516770650274823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216742648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011111517,0.9967667,0.000052923784,0.0017758366,0.00027190647,0.000021114924,0.00012575279,0.0000034339728,0.00087122194],"genre_scores_gemma":[0.002283564,0.9962179,0.00019284963,0.0009249277,0.000107222804,0.000019897048,0.000077964534,0.0000032683197,0.00017230015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948265,0.0009660052,0.0010203808,0.00033925887,0.0024996148,0.00034821537],"domain_scores_gemma":[0.9700523,0.013222781,0.0027815609,0.0004240959,0.012849001,0.00067015964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010047473,0.0009305852,0.0030619886,0.008630879,0.0013298494,0.0035581277,0.002489397,0.0024918814,0.004254906],"category_scores_gemma":[0.032574475,0.0007599048,0.0018463202,0.014738117,0.0015344474,0.0018516075,0.0009110369,0.00298817,0.0005976933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003064885,0.000056479188,0.00080033817,0.203462,0.0009446386,0.0002612787,0.00039687759,0.0012568928,0.00035721075,0.01869692,0.13034853,0.6431123],"study_design_scores_gemma":[0.000060116483,0.00006958016,0.0028543377,0.18560745,0.0013567539,0.0003087146,0.00020111466,0.00017797611,0.0002464355,0.0017739042,0.80728966,0.000053830794],"about_ca_topic_score_codex":0.41025195,"about_ca_topic_score_gemma":0.52501476,"teacher_disagreement_score":0.96679574,"about_ca_system_score_codex":0.033204254,"about_ca_system_score_gemma":0.10257329,"threshold_uncertainty_score":0.815728},"labels":[],"label_agreement":null},{"id":"W4229584754","doi":"10.5639/gabij.2014.0401.012","title":"Comparison of biosimilars guidelines","year":2014,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.14024363653818273,"score_gpt":0.40170539137391414,"score_spread":0.2614617548357314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229584754","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23598784,0.13258295,0.036295574,0.04337719,0.005559584,0.0035092044,0.024465227,0.0015729433,0.5166495],"genre_scores_gemma":[0.75778365,0.06491958,0.06842047,0.045347515,0.0014004151,0.0020273742,0.037405565,0.00092933903,0.021766158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9463373,0.011780153,0.010099129,0.0016158645,0.02837744,0.0017900486],"domain_scores_gemma":[0.89509344,0.0314604,0.008797698,0.0038518305,0.058649953,0.0021467065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021846121,0.00034836555,0.00071087934,0.010475836,0.0009775236,0.0038978893,0.001159909,0.0026965698,0.0044349716],"category_scores_gemma":[0.10162722,0.0003145999,0.0012663793,0.008150152,0.00094068475,0.001488692,0.0016256155,0.0023109314,0.0011209522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002396356,0.0006992721,0.027657963,0.00977766,0.0006851972,0.0011104362,0.0034261462,0.0051829163,0.010637434,0.12608485,0.15787722,0.6544646],"study_design_scores_gemma":[0.00035219904,0.0007835051,0.053396173,0.0061021997,0.0005554243,0.001342361,0.0021801745,0.0011301335,0.007160973,0.013275929,0.9135807,0.00014013666],"about_ca_topic_score_codex":0.012976083,"about_ca_topic_score_gemma":0.012402332,"teacher_disagreement_score":0.021846121,"about_ca_system_score_codex":0.0057331542,"about_ca_system_score_gemma":0.013211758,"threshold_uncertainty_score":0.11553466},"labels":[],"label_agreement":null},{"id":"W4400830732","doi":"10.5639/gabij.2022.1103.018","title":"Key factors for successful uptake of biosimilars: Europe and the US","year":2022,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Key (lock); Business; Medicine; Computer science; Computer security; Internal medicine","score_opus":0.039403864860124246,"score_gpt":0.2793923534529661,"score_spread":0.23998848859284183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400830732","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70696473,0.01625986,0.0028045983,0.10437051,0.00065910426,0.00020137223,0.00049943523,0.00014168251,0.16809872],"genre_scores_gemma":[0.9857144,0.0022333418,0.0012078334,0.00818968,0.00017651868,0.000028078388,0.00013713035,0.000051039755,0.002262021],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879958,0.0041557606,0.0012158169,0.0008757394,0.003811988,0.0019448741],"domain_scores_gemma":[0.9525378,0.023716202,0.0075927246,0.0009640972,0.008828498,0.0063606882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014554012,0.00017676654,0.00026471165,0.0013983991,0.001367088,0.0046126363,0.000597844,0.0023968893,0.012757488],"category_scores_gemma":[0.040251873,0.0001880854,0.00039451994,0.0022381148,0.0017558903,0.0034604068,0.0025423707,0.0023534903,0.0009798253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013574455,0.0007515126,0.5066508,0.0013536814,0.00020676268,0.0023154258,0.016112318,0.0012164918,0.00469802,0.038126625,0.056902487,0.37030846],"study_design_scores_gemma":[0.00014082793,0.0009126651,0.6520777,0.0032458703,0.00019093363,0.0042065876,0.03097465,0.001350635,0.0069951774,0.011542505,0.28819275,0.00016970509],"about_ca_topic_score_codex":0.0126773035,"about_ca_topic_score_gemma":0.009963099,"teacher_disagreement_score":0.014554012,"about_ca_system_score_codex":0.003534749,"about_ca_system_score_gemma":0.006957606,"threshold_uncertainty_score":0.07696986},"labels":[],"label_agreement":null},{"id":"W4401026458","doi":"10.5639/gabij.2023.1202.007","title":"Extrapolation requires reading between the lines","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Extrapolation; Reading (process); Computer science; Mathematics; Statistics; Philosophy; Linguistics","score_opus":0.053973174812983755,"score_gpt":0.3021157404149194,"score_spread":0.24814256560193565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401026458","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002530715,0.010560116,0.07045358,0.3244781,0.3915087,0.0007375209,0.0029413567,0.002933723,0.19385624],"genre_scores_gemma":[0.06655894,0.024580987,0.12573393,0.39009973,0.19217026,0.0023108309,0.005026052,0.006903451,0.18661581],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95728683,0.016082168,0.0074083237,0.0035638392,0.014928562,0.0007303682],"domain_scores_gemma":[0.5665428,0.27463862,0.011827823,0.044268377,0.0994664,0.0032559868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046285756,0.0016020614,0.0016531346,0.0054697776,0.0035253426,0.012427729,0.0030784851,0.0070102755,0.055969946],"category_scores_gemma":[0.36326316,0.0012111466,0.0021466366,0.0036488234,0.0071417745,0.016350072,0.0060587022,0.014162776,0.055241503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027188245,0.000072451425,0.0006597177,0.0014005811,0.000093917064,0.00046207898,0.0022510996,0.00028905325,0.00069160375,0.08520597,0.76408315,0.14451848],"study_design_scores_gemma":[0.00003214956,0.000048026024,0.0003749896,0.0013844176,0.00003919751,0.00016589763,0.00089431414,0.00027779737,0.00060382526,0.06406525,0.93206173,0.00005231434],"about_ca_topic_score_codex":0.0032409024,"about_ca_topic_score_gemma":0.0023957745,"teacher_disagreement_score":0.055969946,"about_ca_system_score_codex":0.0029317834,"about_ca_system_score_gemma":0.0060629128,"threshold_uncertainty_score":0.24478543},"labels":[],"label_agreement":null},{"id":"W4401026462","doi":"10.5639/gabij.2023.1202.008","title":"Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Perception; Medicine; Psychology; Internal medicine; Neuroscience","score_opus":0.039198613817649,"score_gpt":0.3057897446700765,"score_spread":0.2665911308524275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401026462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661863,0.001613326,0.000121919285,0.014522386,0.00008011262,0.000068640904,0.00037225732,0.000015858692,0.017019138],"genre_scores_gemma":[0.9933709,0.0014776492,0.0001927601,0.0033113763,0.000028760298,0.000014408832,0.00014137373,0.000006835131,0.0014558589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909407,0.0013522241,0.00045393468,0.0004246275,0.0056149145,0.0012135798],"domain_scores_gemma":[0.9695509,0.006990295,0.006806552,0.0005173317,0.008308712,0.007826153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006560333,0.00016077101,0.000343587,0.0010899242,0.0052421554,0.0032589626,0.00082242,0.001606918,0.007200493],"category_scores_gemma":[0.02633126,0.00035234555,0.00050346105,0.001887782,0.0025583205,0.0011696545,0.0011975209,0.0019680753,0.00041040813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050981797,0.000433406,0.6999945,0.00072119525,0.0001192484,0.0011806965,0.22303487,0.00037896485,0.0020207344,0.0020255859,0.023411741,0.04616922],"study_design_scores_gemma":[0.00012202957,0.0004522772,0.74038905,0.0008838706,0.00008388049,0.0008683055,0.20826986,0.0006635129,0.00044135927,0.0003145697,0.047351595,0.00015955913],"about_ca_topic_score_codex":0.907632,"about_ca_topic_score_gemma":0.8799736,"teacher_disagreement_score":0.09236801,"about_ca_system_score_codex":0.019928494,"about_ca_system_score_gemma":0.032432172,"threshold_uncertainty_score":0.18582392},"labels":[],"label_agreement":null},{"id":"W4401034735","doi":"10.5639/gabij.2023.1201.006","title":"Non-medical switching of biologicals/biosimilars: Canada, Europe and the US – a webinar report","year":2023,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.025111266278451654,"score_gpt":0.27459839568875927,"score_spread":0.24948712941030762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401034735","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29231685,0.033323765,0.0048097046,0.1870707,0.004773336,0.00386001,0.028033981,0.0013791152,0.44443262],"genre_scores_gemma":[0.7882318,0.03199214,0.006464812,0.044358887,0.0011221974,0.0007927991,0.019220188,0.0004357483,0.10738133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924819,0.00093861716,0.00041447158,0.00028534402,0.0042364267,0.0016432056],"domain_scores_gemma":[0.97133327,0.004311473,0.0010609764,0.000280772,0.01841926,0.0045941942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010285316,0.00043847424,0.0002336548,0.0020361508,0.00340589,0.0039022057,0.0008976049,0.0017175531,0.015229515],"category_scores_gemma":[0.014810796,0.000301557,0.00045632524,0.0028938612,0.000950691,0.0015475552,0.0019165319,0.0023710886,0.0015475478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061081816,0.0008351606,0.036697015,0.0019311369,0.000058400154,0.0017399006,0.011021251,0.0008905143,0.0017024289,0.005183709,0.6591002,0.28022957],"study_design_scores_gemma":[0.00008705141,0.00020854606,0.10684565,0.0017553696,0.000043359632,0.0006181066,0.018756237,0.0009055874,0.0017843412,0.00057762006,0.8683072,0.00011085477],"about_ca_topic_score_codex":0.8560333,"about_ca_topic_score_gemma":0.8854425,"teacher_disagreement_score":0.14396667,"about_ca_system_score_codex":0.030895792,"about_ca_system_score_gemma":0.09490718,"threshold_uncertainty_score":0.28962898},"labels":[],"label_agreement":null}]}